Follow-The-Filings

Security · featured owners

OCUL

Ocular Therapeutix Inc. COM Equity as of 2026 Q1 among managers we track

  • 2 Owners
  • Max 0.6%
  • $7M
  • 1 new 1 exit

Who owns this now

Largest portfolio weights among featured holders · max 0.6% (Nehal Chopra - Ratan Capi...) · not free-float ownership

  1. Nehal Chopra new 0.6%
  2. James Silverman 0.5%

holders

sorted by % of portfolio · long equity only · exits show last held size · open a manager for their book

history
Nehal Chopra - Ratan Capital Management 2026 Q1 0.6% New 0.6% 188,775 $2M hist
James Silverman - Opaleye Management 2026 Q2 stale 0.5% Hold 600,000 $6M hist
Farallon Capital Management exited 2026 Q2 last 2026 Q1 0% Exit 0.00 pp 18,000 $152K hist

2 current · 1 exited last period · options excluded

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $58.44M $63.72M $51.95M
Gross profit * $53.16M $58.1M $45.38M
Gross margin * 91.0% 91.2% 87.3%
Net income -$80.74M -$193.51M -$265.94M
Net margin * -138.1% -303.7% -511.9%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $232.24M $440.99M $782.13M
Total non-current assets * $19.82M $16.95M $25.93M
Total assets $252.06M $457.94M $808.06M
Total current liabilities $34.9M $41.35M $50.81M
Total non-current liabilities * $126.03M $101.24M $102.94M
Total equity $91.13M $315.34M $654.31M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$70.23M -$134.68M -$204.88M
Cash from investing -$6.09M -$1.29M -$11.88M
Cash from financing $169.83M $332.11M $561.72M
Net change in cash $93.51M $196.14M $344.96M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders